



# Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of  
malaria RDTs: Round 2 (2009)



# Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of  
malaria RDTs: Round 2 (2009)

**WHO Library Cataloguing-in-Publication Data :**

Malaria rapid diagnostic test performance: results of WHO product testing malaria RDTs: round 2 (2009).

1.Malaria - diagnosis. 2.Antimalarials - therapeutic use. 3.Malaria - drug therapy. 4.Diagnostic tests, Routine. 5.Reagent kits, Diagnostic - utilization.. 6.Sensitivity and specificity. I.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. II.Centers for Disease Control (U.S.). III.Foundation for Innovative New Diagnostics.

ISBN 978 92 4 159946 7

(NLM classification: WC 750)

**Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2010**

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

The views expressed in this health information product are those of the authors and do not necessarily reflect those of WHO, including TDR. WHO, including TDR, and the authors of this health information product make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR, or the authors. WHO, including TDR, and the authors accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Layout: Bruno Duret

Printed in Philippines

# Contents

ACKNOWLEDGEMENTS	VIII
ABBREVIATIONS	X
1. SUMMARY PERFORMANCE OF MALARIA RDTs: WHO PRODUCT TESTING: ROUNDS 1 AND 2	1
1.1. Introduction	1
1.2. The WHO Product Testing Programme	1
1.3. Results of the Evaluation	2
1.4. Summary of outcomes	3
1.5. Use of these Results	3
2. WHO MALARIA RDT PRODUCT TESTING: ROUND 2 EXECUTIVE SUMMARY	11
2.1. Introduction	11
2.2. The WHO Product Testing Programme	11
2.3. Results of the Evaluation	11
2.4. Use of these Results	12
3. BACKGROUND	13
4. OBJECTIVE	14
5. MATERIALS AND METHODS	15
5.1. Test selection	15
5.2. Outline of the Product Testing Protocol	16
5.3. Evaluation panels	16
5.4. RDT registration	17
5.5. Specimen panel registration	17
5.6. Test phases	18
5.7. Performing rapid tests	18
5.8. Interpretation of results	18
6. DATA MANAGEMENT	19
7. QUALITY ASSURANCE	20
8. ETHICAL CONSIDERATIONS	20
9. DATA ANALYSIS	21
9.1. Measures of parasite detection: parasite detection score and positivity rates	21
9.2. False-positive results	21
9.2.1. Incorrect species identification	21
9.2.2. False-positives from <i>Plasmodium</i> -negative samples	21
9.3. Band intensity	21
9.4. Lot agreement	21
9.5. Invalid tests	22
9.6. Heat (thermal) stability	22

<b>10. LABORATORY VERSUS FIELD-BASED MALARIA RDT EVALUATIONS</b>	<b>22</b>
<b>11. RESULTS</b>	<b>23</b>
11.1. Summary	23
11.2. Phase 1 - <i>P. falciparum</i> culture panel	26
11.3. Phase 2 - Wild-type <i>P. falciparum</i> and <i>P. vivax</i> and <i>Plasmodium</i> spp. negative samples	27
11.3.1. <i>P. falciparum</i> detection	27
11.3.2. <i>P. vivax</i> detection	28
11.3.3. Combined detection of <i>P. falciparum</i> and <i>P. vivax</i>	29
11.3.4. <i>P. falciparum</i> and <i>P. vivax</i> positivity rate	29
11.3.5. Band intensity	30
11.3.6. False-positive rates	31
<b>12. HEAT STABILITY</b>	<b>33</b>
12.1. <i>P. falciparum</i> test lines	35
12.2. Pan-specific test lines	37
<b>13. EASE OF USE DESCRIPTION</b>	<b>38</b>
<b>14. DISCUSSION OF KEY FINDINGS</b>	<b>41</b>
14.1. Panel Detection Score (PDS) and its relationship to sensitivity	41
14.2. False-positive rate and specificity	42
14.3. Heat (thermal) stability	42
14.4. Ease of use description	43
14.5. Inter-lot variability	43
14.6. Target antigens and species	43
<b>15. USING THESE RESULTS TO ENSURE QUALITY OF DIAGNOSIS IN THE FIELD</b>	<b>44</b>
15.1. Beyond procurement	44
15.2. Lot testing	45
<b>16. CONCLUSIONS</b>	<b>45</b>
<b>17. REFERENCES</b>	<b>46</b>
<b>ANNEXES</b>	<b>47</b>
Annex 1: Characteristics of malaria rapid diagnostic tests in the evaluation	48
Annex 2: malaria RDT guide to results interpretation	50
Annex 3: Phase 1 results	60
Annex 4: Phase 2 results	62
Annex 5: Example algorithm for selecting a malaria RDT	78
Annex 6: Introducing RDT-based malaria diagnosis into national programmes	80

# FIGURES

- Figure S1: Malaria RDT performance in Phase 2 of Rounds 1 and 2 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure S2: Malaria RDT performance in Phase 2 of Rounds 1 and 2 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure 1: Mode of action of antigen-detecting malaria RDTs
- Figure 2: Network of specimen collection, characterization and testing sites
- Figure 3: Malaria RDT Product Testing Overview
- Figure 4a: Origin of Phase 2 *P. falciparum* wild-type (clinical) samples
- Figure 4b: Origin of Phase 2 *P. vivax* wild-type (clinical) samples
- Figure 5: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 200 parasites/μl
- Figure 6: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 2000 parasites/μl
- Figure 7: Phase 1 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 8: Phase 2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 9: Phase 2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (aldolase, pLDH, aldolase + pLDH)
- Figure 10: Phase 2 *P. falciparum* panel detection score and positivity rate at 200 parasites/μl
- Figure 11: Phase 2 *P. vivax* panel detection score and positivity rate at 200 parasites/μl
- Figure 12: Phase 2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples
- Figure 13: Phase 2 *Plasmodium* spp. (*pan* or *P. vivax* test line) false-positive rate against clean-negatives
- Figure 14: Phase 2 *P. falciparum* false-positive rate versus *P. falciparum* panel detection score at low (200) parasite density (parasites/μl)
- Figure 15: Phase 2 *P. vivax* false-positive rate versus *P. vivax* panel detection score at low (200) parasite density (parasites/μl)
- Figure 16: Heat stability of *P. falciparum* specific test line of *P. falciparum* only tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 17: Heat stability of *P. falciparum* specific test line of *P. falciparum* tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 18: Heat stability of *P. falciparum* specific test line in combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 19: Heat stability of *P. falciparum* specific test line in combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 20: Heat stability of pan-line of pan-specific tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 21: Heat stability of pan-line of pan-specific tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 22: Heat stability of pan-line of combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 23: Heat stability of pan-line of combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation.
- Figure A6.1: Example malaria RDT implementation budget

# TABLES

Table S1:	Malaria RDT Phase 2 performance in Rounds 1 and 2 against wild-type (clinical) samples containing <i>P. falciparum</i> and <i>P. vivax</i> at low (200) and high (2000 or 5000) parasite densities (parasites/ $\mu$ l) and clean-negative samples
Table S2:	Malaria RDT Rounds 1 and 2 heat stability results on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite density (parasites/ml). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table 1:	Manufacturers and products accepted into Round 2 of WHO Malaria RDT Product Testing Programme
Table 2:	Characteristics of <i>Plasmodium</i> spp. negative specimens
Table 3:	Summary Phase 1 performance of malaria RDTs against 20 cultured <i>P. falciparum</i> lines at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table 4:	Summary Phase 2 performance of malaria RDTs against wild-type (clinical) <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l) and <i>Plasmodium</i> spp. negative samples
Table 5:	Heat stability testing results for 27 malaria RDTs on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite densities (parasites/ $\mu$ l). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table 6:	Ease of use description of 29 malaria RDTs
Table A3.1:	Lot variability in positive results against <i>P. falciparum</i> culture samples at low (200) and high (2000 or 5000) parasite densities (parasites/ $\mu$ l)
Table A3.2:	Distribution of test band intensity scores (0–4) against Phase 1 <i>P. falciparum</i> cultured parasites at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table A4.1:	Lot variability in positive results against Phase 2 wild-type <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table A4.2:	Distribution of test band intensity (0–4) scores against Phase 2 wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table A4.3:	Distribution of Pan/Pv test band intensity (0–4) scores for Phase 2 wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table A4.4:	Panel detection score of Phase 2 wild-type <i>P. falciparum</i> in low (200) and high (2000) parasite densities (parasites/ $\mu$ l) by continent
Table A4.5:	Phase 2 <i>P. falciparum</i> test line false-positive rates for wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)
Table A4.6:	Phase 2 Pan (or <i>P. vivax</i> ) test line false-positive rate for non Pf infection on wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite densities (parasites/ $\mu$ l)

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29132](https://www.yunbaogao.cn/report/index/report?reportId=5_29132)

